Breaking News: Johnson & Johnson (NYSE: JNJ) delivers another dividend increase despite geopolitical shocks, raising quarterly payouts 3.1% to $1.34 per share. The pharmaceutical giant's 64th straight hike during market turbulence reinforces its status as a dividend king, with 50 years of unbroken shareholder rewards. This move signals JNJ's resilience as a cash-flow fortress even as global markets reel from the Israel-Iran conflict.

Why Did Johnson & Johnson Stock Dip This Week?

The recent price weakness is linked to the company’s never-ending lawsuits filed by customers against its products. Recently, a Federal Judge in Texas dismissed the pharma company’s attempt to settle around 70,000 lawsuits linked to its talc products and cancer. This gave the medical giant a legal setback as the legal troubles refused to go away. Johnson & Johnson stock will always be under pressure, as the company is forced to fight thousands of individual lawsuits.

Investors are concerned about the financial exposure the medical giant has to go through to fight the litigation. There is no doubt that many more individual cases will pile up, creating further legal headwinds. The Federal Judge rejected the company’s third attempt in the talcum powder-cancer case is causing trouble for Johnson & Johnson stock in April.